Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Genzyme Gains Breakthrough Designation for Rare Disease Drug

By Drug Discovery Trends Editor | June 5, 2015

The Food and Drug Administration (FDA) has granted Genzyme a breakthrough therapy designation for a drug called olipudase alfa, an enzyme-replacement therapy intended for the treatment of Niemann-Pick Disease Type B (NPB) otherwise known as acid sphingomyelinase deficiency.

Genzyme touted the label in a statement,explaining that this life-threatening disease occurs when there is, “insufficient activity of the enzyme acid sphingomyelinase (ASM), which results in toxic accumulation of sphingomyelin.”

An inability to metabolize sphingomyelin, along with a buildup of the lipid within the cell,s can lead to cell death and malfunctioning of major organ systems, according to the company’s announcement. 

Olipudase alfa is being designed to address the underlying cause of NPB and serve as a substitute for the missing enzyme so the body can breakdown the sphingomyelin. There are currently no approved treatments for this disorder. 

FierceBiotech reports the FDA decided to give the tag to Genzyme after five patients demonstrated early signs of efficacy in a Phase 1b trial. 

A breakthrough therapy designation will help Genzyme quickly move through the rest of the regulatory process. 

Meanwhile, the drugmaker has begun enrollment for a Phase 1/2 pediatric study of olipudase alfa and is preparing to launch a Phase 2/3 adult study in the second half of 2015.

READ MORE: AbbVie Receives Breakthrough Designation for Cancer Drug


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE